ArticleThe Lancet. Infectious diseases2022

Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adults.

Saskia C van der Boor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.